ELI LILLY AND COMPANY Cash and Restricted Cash
ELI LILLY AND COMPANY (LLY) had Cash and Restricted Cash of $1.70 billion as of 2020-03-31, per its 10-Q filed 2020-05-01.
Discontinued › Cash Flow › Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2020-05-01
- 2020-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $1.70B.
- 2019-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $2.34B.
- 2019-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $2.04B.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2020-03-31 | $1.70B 10-Q · filed 2020-05-01 |
| 2019-12-31 | $2.34B 10-Q · filed 2020-05-01 |
| 2019-03-31 | $2.04B 10-Q · filed 2020-05-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |